Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
229 hedge funds and large institutions have $309M invested in Sorrento Therapeutics, Inc. in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 78 increasing their positions, 47 reducing their positions, and 26 closing their positions.
222% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $3.53M
66% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 47
4% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 26
1% more capital invested
Capital invested by funds: $306M → $309M (+$2.77M)
3% less funds holding
Funds holding: 235 → 229 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.86M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.64M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.3M |
| 5 |
Citigroup
New York
|
+$2.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$3.86M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.35M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.33M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.78M |
| 5 |
Two Sigma Investments
New York
|
-$1.36M |
SRNE Hedge Fund Activity: Q2 2022 in Review
229 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q2 2022, worth a combined $309M — up 0.91% from $306M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SRNE positions and 26 closed out — a net gain of 1 holder — while 78 added to existing stakes and 47 trimmed.
The largest buyer was BlackRock, adding an estimated $20.6M. The largest seller was Marshall Wace, exiting entirely with an estimated $3.86M sold.
- 229 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q2 2022, down from 235 in Q1 2022.
- Funds reported $309M of Sorrento Therapeutics, Inc. stock for Q2 2022, up 0.91% quarter-over-quarter.
- 27 funds opened new Sorrento Therapeutics, Inc. positions in Q2 2022 and 26 closed out, a net change of +1 holder.
- The largest Sorrento Therapeutics, Inc. buyer in Q2 2022 was BlackRock, an estimated $20.6M added.
- The largest Sorrento Therapeutics, Inc. seller in Q2 2022 was Marshall Wace, an estimated $3.86M sold.
Based on aggregated 13F filings for Q2 2022.